Compare ALM & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALM | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | N/A | 2020 |
| Metric | ALM | OLMA |
|---|---|---|
| Price | $23.36 | $16.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $22.33 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 6.0M | 924.0K |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $817.94 | N/A |
| Revenue Next Year | $158.05 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.16 | $3.89 |
| 52 Week High | $24.41 | $36.26 |
| Indicator | ALM | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 50.09 |
| Support Level | $5.32 | $13.11 |
| Resistance Level | N/A | $16.99 |
| Average True Range (ATR) | 1.62 | 0.81 |
| MACD | 0.76 | 0.46 |
| Stochastic Oscillator | 89.49 | 75.10 |
Almonty Industries Inc is engaged in the mining, processing, and shipping of tungsten concentrate from its Los Santos tungsten mine located near Salamanca, Spain - the Los Santos Mine, the processing and shipping of tungsten concentrate from its Panasqueira tin and tungsten mine in Covilha, Castelo Branco, Portugal - the Panasqueira Mine, the evaluation of its Valtreixal tin and tungsten mine project located in Western Spain in the province of Zamora - the Valtreixal Mine, as well as the exploration and evaluation of its Sangdong tungsten mine project located in Gangwon Province, Republic of Korea - the Sangdong Mine.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.